APA (7th ed.) Citation

GH, G., S, G., TT, L., YP, W., LR, L., WH, Y., . . . TJ, Z. (2025). Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 dual-target inhibitors for the treatment of triple-negative breast cancer. Bioorganic & medicinal chemistry letters, 128, 130362. https://doi.org/10.1016/j.bmcl.2025.130362

Chicago Style (17th ed.) Citation

GH, Ge, et al. "Discovery and Structural-activity Relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 Dual-target Inhibitors for the Treatment of Triple-negative Breast Cancer." Bioorganic & Medicinal Chemistry Letters 128 (2025): 130362. https://doi.org/10.1016/j.bmcl.2025.130362.

MLA (9th ed.) Citation

GH, Ge, et al. "Discovery and Structural-activity Relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 Dual-target Inhibitors for the Treatment of Triple-negative Breast Cancer." Bioorganic & Medicinal Chemistry Letters, vol. 128, 2025, p. 130362, https://doi.org/10.1016/j.bmcl.2025.130362.